Acceleration of full-thickness wound healing in normal rats by the synthetic thrombin peptide, TP508.
Acceleration of full-thickness wound healing in normal rats by the synthetic thrombin peptide, TP508.
复制标题
合成凝血酶肽 TP508 加速正常大鼠全层伤口愈合。
DOI：
10.1046/j.1524-475x.2000.00204.x
复制
发表时间：
2000
期刊：
影响因子：
--
通讯作者：
Carney,DH
中科院分区：
文献类型：
--
作者：
Stiernberg,J;Norfleet,AM;Redin,WR;Warner,WS;Fritz,RR;Carney,DH
凝血酶是止血、炎症和组织修复的重要因素。合成凝血酶肽TP 508与高亲和力凝血酶受体结合，并模拟凝血酶在组织损伤部位的细胞效应。单次局部应用0.1 μg TP 508（14 pmol/cm 2）治疗正常大鼠的全层切除伤口可重复加速伤口闭合，到第7天，伤口平均闭合比对照组多39%（p< 0.001）。在第7天和第10天，用1.0 μg TP 508处理的伤口分别比对照小35%和43%（p< 0.001）。TP 508处理伤口的早期闭合率比溶剂处理伤口高约40%（20与14 mm 2/天），并在第7天保持较高水平。在用TP 508处理的伤口中，闭合后的断裂强度比单独用盐水处理的伤口稍大（15-23%）。组织学比较表明，TP 508在损伤后24小时内增强了炎症细胞向伤口部位的募集。TP 508治疗还增强了损伤组织的血管再生，如在第7天通过肉芽组织中功能性血管的较大尺寸和通过血管向伤口的定向发育所证明的。这些研究提出了TP 508在临床上可用于管理开放性伤口的可能性。
Thrombin is an essential factor in hemostasis, inflammation, and tissue repair. The synthetic thrombin peptide, TP508, binds to high‐affinity thrombin receptors and mimics cellular effects of thrombin at sites of tissue injury. Treatment of full‐thickness excisional wounds in normal rats with a single topical application of 0.1 μg TP508 (14 pmol/cm2) reproducibly accelerates wound closure, yielding wounds that on average close 39% more than controls by day 7 (p< 0.001). Wounds treated with 1.0 μg TP508 are 35% and 43% (p< 0.001) smaller than controls on day 7 and 10, respectively. The early rate of closure is ~40% greater in TP508‐treated than vehicle‐treated wounds (20 versus 14 mm2/day) and remains higher through day 7. Breaking strength after closure is slightly greater (15–23%) in wounds treated with TP508 than with saline alone. Histologic comparisons show that TP508 enhances recruitment of inflammatory cells to the wound site within 24 hours post‐injury. TP508 treatment also augments revascularization of injured tissue, as evidenced at day 7 by the larger size of functional vessels in the granulation tissue and by the directed development of blood vessels to wounds. These studies raise the possibility that TP508 may be clinically useful in management of open wounds.